Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Short-term Investments (2016 - 2019)

Historic Short-term Investments for Macrogenics (MGNX) over the last 5 years, with Q4 2019 value amounting to $89.3 million.

  • Macrogenics' Short-term Investments rose 60109.15% to $89.3 million in Q4 2019 from the same period last year, while for Dec 2019 it was $89.3 million, marking a year-over-year increase of 60109.15%. This contributed to the annual value of $89.3 million for FY2019, which is 60109.15% up from last year.
  • Per Macrogenics' latest filing, its Short-term Investments stood at $89.3 million for Q4 2019, which was up 60109.15% from $12.7 million recorded in Q4 2018.
  • In the past 5 years, Macrogenics' Short-term Investments registered a high of $192.9 million during Q4 2016, and its lowest value of $12.7 million during Q4 2018.
  • Moreover, its 5-year median value for Short-term Investments was $93.4 million (2017), whereas its average is $106.2 million.
  • As far as peak fluctuations go, Macrogenics' Short-term Investments plummeted by 8636.42% in 2018, and later soared by 60109.15% in 2019.
  • Over the past 5 years, Macrogenics' Short-term Investments (Quarter) stood at $142.9 million in 2015, then soared by 35.01% to $192.9 million in 2016, then plummeted by 51.58% to $93.4 million in 2017, then crashed by 86.36% to $12.7 million in 2018, then surged by 601.09% to $89.3 million in 2019.
  • Its Short-term Investments stands at $89.3 million for Q4 2019, versus $12.7 million for Q4 2018 and $93.4 million for Q4 2017.